List of Excipients in Branded Drug MITIGARE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Specialty USA Inc	MITIGARE	colchicine	59467-318	ANHYDROUS LACTOSE
Hikma Specialty USA Inc	MITIGARE	colchicine	59467-318	CELLULOSE, MICROCRYSTALLINE
Hikma Specialty USA Inc	MITIGARE	colchicine	59467-318	D&C YELLOW NO. 10
Hikma Specialty USA Inc	MITIGARE	colchicine	59467-318	FD&C RED NO. 3

Mitigare Excipient Strategy and Commercial Opportunities in Colchicine Capsules

Last updated: August 10, 2026

Mitigare is a 0.6 mg oral colchicine capsule approved in the U.S. for gout flares and familial Mediterranean fever. Its commercial opportunity is driven less by novel active-ingredient protection than by reliable low-dose manufacturing, supply continuity, capsule differentiation, pediatric or adherence-oriented presentations, and control of excipient-related quality risks. The strongest opportunities are authorized-generic supply, differentiated colchicine capsules, fixed-dose or co-packaged gout products, and improved formulations that reduce gastrointestinal intolerance.

What is Mitigare and how is it positioned commercially?

Mitigare contains colchicine, an established anti-inflammatory drug with a narrow therapeutic index. The product is an immediate-release capsule administered orally at a 0.6 mg strength. The U.S. label identifies gout flare prophylaxis and familial Mediterranean fever as approved uses.[1]

Product attribute	Mitigare
Active ingredient	Colchicine
Strength	0.6 mg
Dosage form	Oral capsule
FDA application	NDA 204820
Main U.S. indications	Gout flares and familial Mediterranean fever
Regulatory pathway	505(b)(2) application
Reference-product market	Colcrys tablets and generic colchicine tablets
Primary formulation issue	Accurate, uniform delivery of a potent low-dose active
Main commercial competitors	Generic colchicine tablets, Colcrys, other branded or authorized-generic colchicine products

Mitigare’s capsule format distinguishes it from the tablet-dominant colchicine market. That difference has limited clinical significance for many patients but can matter in pharmacy substitution, patient preference, swallowing behavior, packaging, and contracting.

Colchicine has a narrow margin between therapeutic and toxic exposure. The label carries prominent warnings involving overdose, neuromuscular toxicity, blood dyscrasias, hepatic or renal impairment, and interactions with strong CYP3A4 or P-glycoprotein inhibitors.[1] Excipient strategy therefore must prioritize dose uniformity, dissolution consistency, stability, and manufacturing control over cosmetic differentiation.

What excipients are used in Mitigare capsules?

The Mitigare prescribing information identifies inactive ingredients used in the capsule formulation. Public labeling should be treated as the controlling source for the marketed composition, while exact quantitative amounts and process parameters are generally not disclosed in product labeling.[1]

The formulation uses conventional oral solid-dose excipients rather than a novel delivery platform. Relevant excipient functions include:

Excipient category	Likely function in Mitigare-type capsule formulation	Commercial relevance
Diluent or filler	Provides capsule fill mass around the low colchicine dose	Supports content uniformity and manufacturing robustness
Microcrystalline cellulose or comparable filler	Improves powder handling and fill consistency	Important for low-dose uniformity
Lubricant	Reduces friction during blending and capsule filling	Excess use can slow dissolution
Gelatin capsule shell	Provides the oral dosage-form container	Creates vegetarian, allergen, and market-access considerations
Titanium dioxide or permitted colorants	Controls capsule appearance and identification	Supports brand recognition and error reduction
Water	May be present in excipients or capsule shell at controlled levels	Affects stability and dissolution

The core formulation challenge is the ratio between a very small colchicine dose and the total capsule fill. A 0.6 mg dose requires robust blending and segregation controls. Excipient particle size, density, electrostatic behavior, and flow properties can materially affect dose uniformity during blending, transfer, and encapsulation.

Why does low-dose colchicine create excipient risk?

Colchicine is pharmacologically potent, so small absolute deviations can have clinical significance. The formulation must control:

• Blend uniformity.
• Segregation during equipment transfer.
• Powder adherence to manufacturing surfaces.
• Capsule-fill weight variation.
• Dissolution across the product shelf life.
• Assay and degradation products.
• Cross-contamination during multiproduct manufacturing.

A high-load formulation is not automatically superior. A larger dose of active relative to excipients could reduce dilution-related segregation, but it may worsen flow, content uniformity, or capsule-fill behavior. A lower drug load can improve handling when the excipient system is engineered correctly.

What excipient strategy best supports Mitigare commercialization?

The strongest strategy is a conservative, performance-driven excipient system built around dose uniformity and manufacturing reproducibility.

Use a robust capsule-fill platform

Microcrystalline cellulose, lactose, starch-based materials, or co-processed excipients can serve as diluents, but the selection should be based on measured performance rather than low cost alone. Key screening variables include:

• Bulk and tapped density.
• Carr index and Hausner ratio.
• Particle-size distribution.
• Moisture uptake.
• Electrostatic charge.
• Compatibility with colchicine.
• Lubricant sensitivity.
• Dissolution impact.

Co-processed excipients may create a more consistent commercial manufacturing platform, particularly when they improve flow without requiring high lubricant levels. The tradeoff is higher excipient cost, supplier dependence, and potential regulatory change-control burdens.

Control lubricant levels

Magnesium stearate is widely used in hard capsules, but excessive lubrication can create hydrophobic particle surfaces and slow drug release. A commercial formulation should establish a narrow operating range for lubricant concentration, blending time, and shear exposure.

For Mitigare, dissolution control is commercially important because a formulation that releases colchicine more slowly or more variably could create regulatory and substitution problems. Release should remain consistent with the approved immediate-release profile.

Evaluate lactose and allergen positioning

Lactose is a common oral solid-dose excipient, but it creates several commercial considerations:

• Patients with severe lactose intolerance may seek alternatives.
• Dairy-derived excipient statements may affect certain institutional or international markets.
• Supplier changes can affect particle size, moisture, and flow.
• Reducing or eliminating lactose can support a differentiated "lactose-free" positioning if clinically and regulatorily supportable.

A lactose-free Mitigare-compatible capsule could be attractive in hospital formularies, specialty pharmacies, and direct-to-consumer channels. The claim would require formal composition control and compliant labeling. It would not, by itself, establish superior clinical performance.

Consider capsule-shell alternatives

The conventional gelatin capsule is cost-efficient and familiar. Alternative shells, including hypromellose capsules, could support:

• Vegetarian or religious-diet positioning.
• Lower sensitivity to certain storage conditions.
• Reduced dependence on animal-derived materials.
• International market access where gelatin sourcing is restricted.

Hypromellose shells can change moisture transfer, brittleness, dissolution, and machine performance. A shell change would require stability, dissolution, packaging, and potentially bioequivalence assessment depending on the extent of formulation modification.

What formulations are commercially attractive for colchicine?

Several formulation concepts could create opportunities around Mitigare without attempting to replace the core product.

Formulation opportunity	Commercial rationale	Key regulatory or technical barrier
Lactose-free 0.6 mg capsule	Differentiates on excipient profile	Must demonstrate equivalent performance and support labeling claims
Hypromellose capsule	Vegetarian and selected-market positioning	Shell compatibility, dissolution, stability, and manufacturing validation
0.3 mg capsule	Supports dose titration and renal or interaction-sensitive use	Clinical utility, dose accuracy, and new strength approval
0.6 mg sprinkle capsule	Supports patients with swallowing difficulty	Opening stability, uniform distribution, administration instructions
Pediatric-friendly oral granules	Creates a pediatric or caregiver-oriented product	Pediatric formulation development and age-appropriate dosing
Blister-packed capsules	Reduces dosing errors and supports adherence	Packaging qualification and unit-dose economics
Co-packaged flare and prophylaxis regimen	Simplifies initiation and maintenance	Labeling, prescribing, and reimbursement strategy
Modified-release product	Could reduce peak-related intolerance	More complex clinical development and unlikely to be a simple substitution

The most practical near-term opportunities are lactose-free capsules, alternative capsule shells, unit-dose blister packaging, and additional strengths. Modified-release colchicine has greater development risk because any change in exposure could affect safety and efficacy.

What FDA regulatory status applies to Mitigare and colchicine?

Mitigare was approved by FDA through NDA 204820 under the 505(b)(2) pathway.[1] The product’s regulatory value comes from the established colchicine pharmacology combined with the capsule formulation and approved labeling.

The relevant regulatory issues are:

1. NDA supplement risk. Changes to excipients, capsule shell, manufacturing process, or specifications may require a prior-approval supplement, a changes-being-effected supplement, or annual-report treatment depending on the change and applicable FDA guidance.
2. Bioequivalence. A reformulated capsule may require comparative dissolution and, depending on the change, in vivo bioequivalence data.
3. Narrow therapeutic index. FDA may apply heightened scrutiny to dose uniformity, analytical methods, dissolution, and manufacturing controls.
4. Inactive ingredient limits. Proposed excipients must be acceptable for the route, dosage form, and intended maximum daily exposure. FDA’s Inactive Ingredient Database is a screening tool, not a substitute for product-specific justification.[2]
5. Labeling claims. "Lactose-free," "vegetarian," "gluten-free," or similar claims require documented composition and compliant labeling support.

What is the Orange Book status of Mitigare?

The Orange Book identifies approved drug products, therapeutic equivalence evaluations, and patent or exclusivity information where applicable.[3] Mitigare’s commercial position should be evaluated separately from Colcrys because a product’s patent and exclusivity profile depends on its own application, listed patents, and regulatory history.

Colchicine tablets have historically been subject to extensive patent and litigation activity, particularly around Colcrys. That history does not automatically transfer to Mitigare capsules. A Mitigare-focused freedom-to-operate review should examine:

• Current Orange Book entries for NDA 204820.
• Any listed formulation or method-of-use patents.
• Patent-term extensions.
• Regulatory exclusivity periods.
• Approved or tentative ANDAs referencing the product.
• Any settlement or license agreements involving capsule products.

Publicly available product information does not establish a broad, durable composition-of-matter barrier around Mitigare’s conventional excipient system. The commercially relevant protection is more likely to arise from regulatory approval, manufacturing know-how, supplier qualification, process controls, trademarks, and market contracts than from a novel excipient patent.

What patents protect Mitigare and its excipient formulation?

The active ingredient colchicine is an old molecule and does not provide modern composition-of-matter exclusivity. Protection for a product such as Mitigare would more plausibly involve:

• Capsule formulation patents.
• Specific excipient ratios.
• Particle-size or solid-state controls.
• Dissolution profiles.
• Manufacturing processes.
• Packaging systems.
• Method-of-use claims.
• Pediatric or alternate-strength formulations.

A formulation patent is stronger when it links a narrowly defined excipient combination to a measurable technical result, such as improved content uniformity, reduced degradation, controlled dissolution, or improved stability. Broad claims covering ordinary fillers, lubricants, and gelatin shells are vulnerable to written-description, enablement, obviousness, and design-around challenges.

How strong is the Mitigare patent estate?

The estate appears structurally weaker than the patent estates of newer small-molecule drugs because:

• Colchicine is an established active ingredient.
• Conventional capsule excipients are widely used.
• Generic manufacturers can often design around specific excipient selections.
• Regulatory approval does not itself prevent competing development.
• Manufacturing controls may be difficult to enforce as product patents.

The strongest defensible positions would involve a specific, non-obvious low-dose formulation with demonstrated technical advantages, or a manufacturing process that materially improves content uniformity and is difficult to reproduce economically.

When does Mitigare lose exclusivity?

Mitigare’s commercial exclusivity should not be assessed by relying on the exclusivity history of Colcrys. The relevant dates are those associated with NDA 204820, its listed patents, and any FDA-granted exclusivity.

For a conventional colchicine capsule, the likely loss-of-exclusivity pathway is:

Exclusivity layer	Relevance to Mitigare
Active-ingredient exclusivity	Not commercially meaningful because colchicine is long established
NDA regulatory exclusivity	Depends on the application and any granted exclusivity
Listed patents	Must be confirmed in the current Orange Book
Trade dress and trademark	Can be designed around by competitors
Manufacturing know-how	Can delay competition but is not a formal exclusivity right
Distribution contracts	May affect uptake but do not block approval
Formulation patents	Potentially important if valid and technically narrow

The practical conclusion is that Mitigare’s durable commercial defense depends on execution, supply, contracting, and differentiated product design unless enforceable formulation or method patents remain active.

Which companies are challenging Mitigare with generics?

Generic colchicine is available in tablet form, creating direct price pressure even where capsule competition is limited. An ANDA applicant seeking approval of a colchicine capsule could use the applicable reference product pathway and challenge listed patents through Paragraph IV certification if relevant patents are listed.

A generic launch could occur through several scenarios:

1. Tablet substitution pressure. Pharmacies and payers shift patients from Mitigare capsules to lower-cost colchicine tablets.
2. Direct capsule competition. An ANDA applicant develops an equivalent 0.6 mg capsule.
3. Authorized-generic strategy. The NDA holder licenses or supplies a generic version to preserve channel access.
4. Formulation differentiation. A competitor launches a lactose-free, vegetarian, or alternate-strength capsule.
5. Contracting-driven displacement. A payer excludes Mitigare despite limited direct capsule competition.

The principal risk is substitution by generic tablets rather than a single patent challenger. Because colchicine therapy is usually prescribed by strength and active ingredient, dosage-form preference may not prevent formulary conversion.

What Paragraph IV challenges and litigation affect Mitigare?

Paragraph IV risk depends on active Orange Book patents linked to the relevant NDA and on the ANDA applicant’s certification strategy. A complete litigation assessment requires current FDA and federal court records for the specific application.

The principal legal issues are likely to involve:

• Whether any listed patent claims the Mitigare capsule formulation.
• Whether a proposed generic uses the same or a different excipient system.
• Whether the applicant can certify non-infringement or invalidity.
• Whether a 30-month stay applies.
• Whether a settlement includes a launch date, license, or authorized-generic provision.

Colchicine-related litigation can be commercially relevant without directly involving Mitigare. Patent disputes concerning Colcrys, dosing regimens, or other colchicine products may shape payer behavior and generic development, but they should not be treated as Mitigare-specific precedent without a claim-by-claim analysis.

What licensing deals could expand Mitigare’s commercial value?

Licensing opportunities are most credible in four areas:

Regional commercialization

A partner with established specialty-pharmacy or rheumatology coverage could commercialize Mitigare in markets where gout prevalence and colchicine use are high. The capsule format may have value where local tablet competition is weaker.

Authorized generic supply

An authorized-generic agreement could protect volume while reducing payer resistance. The agreement would need to address price corridors, supply obligations, channel allocation, and branding rights.

Alternative capsule technology

A capsule-shell or excipient supplier could license a vegetarian shell, moisture-barrier technology, or low-dose powder platform. The value would depend on measurable stability or manufacturing advantages.

Pediatric and specialty formulations

A 0.3 mg capsule, sprinkle formulation, or age-appropriate dosage form could support licensing with pediatric, rare-disease, or specialty-pharmacy partners. Familial Mediterranean fever provides a niche commercial segment, although the addressable population is much smaller than the broader gout market.

What manufacturing and IP barriers affect Mitigare competition?

Manufacturing barriers are more significant than active-ingredient barriers.

Critical manufacturing controls

• Potent-compound containment.
• Validated cleaning procedures.
• Blend uniformity.
• In-process capsule-weight control.
• Low-dose assay precision.
• Cross-contamination prevention.
• Stability under temperature and humidity stress.
• Reliable gelatin or hypromellose capsule sourcing.

IP and know-how barriers

A manufacturer may protect:

• Order of excipient addition.
• Pre-blending or geometric dilution techniques.
• Lubrication time.
• Encapsulation-machine settings.
• Environmental humidity controls.
• In-process sampling methods.
• Packaging configurations.
• Supplier specifications.

These controls can improve yield and reduce recalls, but trade-secret protection does not prevent a competitor from independently developing an equivalent process.

How does Mitigare compare with Colcrys and generic colchicine?

Factor	Mitigare	Colcrys	Generic colchicine
Active ingredient	Colchicine	Colchicine	Colchicine
Common dosage form	Capsule	Tablet	Primarily tablet
Brand differentiation	Capsule format and labeling	Established branded tablet	Price and payer access
Patent value	Likely formulation- or process-dependent	Historically stronger branded-product patent activity	Usually limited to applicant-specific formulation or process
Main commercial vulnerability	Tablet substitution and price pressure	Patent expiry and generic entry	Commodity pricing
Excipient opportunity	Alternative shell, lactose-free, strengths, packaging	Reformulation or lifecycle extensions	Cost-efficient, compliant formulation
Key buyer decision	Coverage, supply, capsule preference	Brand familiarity and contracting	Lowest net cost

Mitigare can compete where capsule preference, supply reliability, or a differentiated excipient profile matters. It is less defensible in price-sensitive formularies that treat capsules and tablets as interchangeable.

What revenue exposure does Mitigare face?

No product-level revenue figure should be inferred from corporate sales disclosures unless the manufacturer reports Mitigare separately. Revenue exposure depends on:

• Net price after rebates.
• Share of colchicine prescriptions.
• Capsule-versus-tablet substitution.
• Payer coverage.
• Specialty-pharmacy distribution.
• Availability of generic capsules.
• Supply continuity.
• Physician preference.
• Use in familial Mediterranean fever.

The most sensitive revenue event is likely the approval of a directly substitutable generic 0.6 mg capsule combined with a payer mandate for lowest-net-cost colchicine. A generic tablet already limits pricing power across the category.

Key Takeaways

• Mitigare is a 0.6 mg colchicine capsule approved under NDA 204820 for gout flares and familial Mediterranean fever.
• Its formulation value comes from reliable delivery of a potent low-dose active, not from a novel excipient platform.
• The best excipient opportunities are lactose-free formulations, vegetarian capsule shells, additional strengths, sprinkle formats, and unit-dose packaging.
• Low-dose blend uniformity, dissolution, stability, and contamination control are the main technical barriers.
• Generic tablets create substantial commercial pressure even without a direct capsule competitor.
• Mitigare-specific patent strength depends on current Orange Book listings and claim scope; conventional excipients alone provide a weak barrier.
• Authorized-generic supply, specialty distribution, and formulation lifecycle management are more credible commercial defenses than broad patent exclusivity.
• The highest-value development path is a differentiated capsule with measurable manufacturing, adherence, or market-access advantages.

FAQs

Can Mitigare be reformulated without a new clinical trial?

Some excipient changes may proceed through a CMC supplement with comparative dissolution and stability data, while larger changes may require bioequivalence or additional clinical support. The regulatory category depends on the nature and extent of the change.

Is a lactose-free colchicine capsule commercially viable?

Yes. A lactose-free capsule could address excipient preferences and support specialty-pharmacy positioning, but the formulation must preserve dose uniformity, dissolution, stability, and manufacturing yield.

Could a 0.3 mg Mitigare capsule reduce colchicine toxicity?

A lower-strength capsule could improve dose adjustment in patients with renal or hepatic impairment or interacting medicines. It would not eliminate toxicity risk and would require an approved dosing strategy and product-specific regulatory support.

Does a capsule formulation qualify for separate generic approval from colchicine tablets?

A capsule applicant must satisfy the applicable FDA reference-product and bioequivalence requirements. Differences in dosage form, inactive ingredients, and release characteristics can affect the development pathway.

What is the strongest lifecycle strategy for Mitigare?

The strongest practical strategy combines an excipient-differentiated capsule, reliable supply, unit-dose packaging, additional strengths, payer contracting, and an authorized-generic plan. A narrowly drafted formulation or manufacturing patent can reinforce that strategy but is unlikely to replace it.

References

1. U.S. Food and Drug Administration. (2014). Mitigare (colchicine) capsules, prescribing information. FDA.
2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
4. U.S. Food and Drug Administration. (2016). SUPAC-IR: Immediate-release solid oral dosage forms: Scale-up and post-approval changes. FDA.
5. U.S. Food and Drug Administration. (2023). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin. FDA.